KaloBios prices upsized deal at $8, at low end of the range

By Renaissance Capital,

Shutterstock photo

KaloBios Pharmaceuticals, which is developing monoclonal antibodies to treat respiratory diseases and cancer, raised $70 million by offering 8.8 million shares (500,000 more than expected) at $8, the low end of the revised range of $8 to $9. The company will command a market value of $191 million and an enterprise value of $103 million. KaloBios Pharmaceuticals will begin trading on Thursday on the NASDAQ under the symbol KBIO. Leerink Swann was the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: KBIO

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com